Antiplatelet therapy strategies for ischemic stroke
Abstract
The paper considers the key areas of antithrombotic platelet therapy for ischemic stroke (IS). Antithrombotic therapy is shown to be a multistep and multidisciplinary strategy of treatment for patients with IS that begins with the first symptoms of the disease and continues throughout life. Each stage, including fibrinolytic therapy, early administration of antiplatelet and anticoagulant drugs, and personalized antithrombotic prevention of recurrent cerebral disorders, is important in itself and serves a single goal. Untimately, all efforts should be aimed at reducing mortality rates in the acute phase of stroke and the functional dependence of a patient and at preventing venous thromboses, recurrent stroke, and all cardiovascular events to increase the duration and quality of life. Fibrinolytic therapy increases the patient's chances for a full neurological recovery and improves the quality of later life. Antiplatelet drugs reduce the risk of cardiovascular death, early recurrences of stroke, and recurrent noncardioembolic stroke. Parenteral anticoagulants in acute stroke decrease the risk of venous thrombosis/thromboembolism, oral anticoagulants reduce that of recurrent cardioembolic stroke.
About the Authors
M. Yu. Maksimova
Neurology Research Institute, Moscow
Russian Federation
Russian Federation
80, Volokolamskoe Shosse, Moscow 125367
A. V. Fonyakin
Neurology Research Institute, Moscow
Russian Federation
Russian Federation
80, Volokolamskoe Shosse, Moscow 125367
L. A. Geraskina
Neurology Research Institute, Moscow
Russian Federation
Russian Federation
80, Volokolamskoe Shosse, Moscow 125367
References
1. Суслина ЗА, Пирадов МА, редакторы. Инсульт: диагностика, лечение, профилактика. Москва: МЕДпресс-информ; 2009. 288 с. [Suslina ZA, Piradov MA, editors. Insul't: diagnostika, lechenie, profilaktika [Stroke: diagnostics, treatment, prevention]. Moscow: MEDpress-inform; 2009. 288p.]
2. The European Stroke Organization (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attacks 2008. Cerebrovasc Dis. 2008;25(5):457-507. doi: 10.1159/000131083. Epub 2008 May 6.
3. Суслина ЗА., Гулевская ТС, Максимова МЮ, Моргунов ВА. Нарушения мозгового кровообращения. Диагностика, лечение, профилактика. Москва: МЕДпресс-информ; 2016. 536 с. [Suslina ZA., Gulevskaya TS, Maksimova MYu, Morgunov VA. Narusheniya mozgovogo krovoobrashcheniya. Diagnostika, lechenie, profilaktika [Violations of cerebral circulation. Diagnosis, treatment, prevention]. Moscow: MEDpress-inform; 2016. 536 p.].
4. Jauch EC, Saver JL, Adams HP, et al. Guidelines for the Early Management of Patients with Acute Ischemic Stroke. Stroke. 2013 Mar;44(3):870-947. doi: 10.1161/STR. 0b013e318284056a. Epub 2013 Jan 31.
5. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995 Dec 14;333(24):1581-7.
6. IST-3 collaborative group. Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial. Lancet Neurol. 2013 Aug;12(8):768-76. doi: 10.1016/S1474-4422(13)70130-3. Epub 2013 Jun 21.
7. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr; American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009 Aug;40(8):2945-8. doi: 10.1161/ STROKEAHA.109.192535. Epub 2009 May 28.
8. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008 Sep 25;359(13):1317-29. doi: 10.1056/NEJMoa0804656.
9. Adams H, Del Zoppo G, Alberts M, et al. Guidelines for the management of adults with ischemic stroke. Stroke. 2007 May;38(5): 1655-711. Epub 2007 Apr 12.
10. Lees K, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010 May 15;375(9727): 1695-703. doi: 10.1016/S0140-6736(10)60491-6.
11. Скворцова ВИ, Голухов ГН, Губский ЛВ и др. Системная тромболитическая терапия при ишемическом инсульте. Журнал неврологии и психиатрии им. С.С. Корсакова. 2006;106(12):24-31. [Skvortsova VI, Golukhov GN, Gubskii LV, et al. Systemic thrombolytic therapy in ischemic stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2006;106(12): 24-31. (In Russ.)].
12. Домашенко МА, Максимова МЮ, Лоскутников МА и др. Системный медикаментозный тромболизис в острейшем периоде ишемического инсульта. Анналы клинической и экспериментальной неврологии. 2008;(2):5-12. [Domashenko MA, Maksimova MYu, Loskutnikov MA, et al. Systemic pharmacological thrombolysis in acute ischemic stroke. Annaly klinicheskoi i eksperimental'noi nevrologii. 2008;(2):5-12. (In Russ.)].
13. Домашенко МА, Максимова МЮ, Лоскутников МА и др. Механизмы реперфузии при внутривенной тромболитической терапии у пациентов с ишемическим инсультом. Неврология, нейропсихиатрия, психосоматика. 2012;4(4):53-8. [Domashenko MA, Maksimova MYu, Loskutnikov MA, et al. The mechanisms of reperfusion during in stroke patients treated with intravenous thrombolysis. Nevrologiya, neiropsikhiatriya, psihosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2012;4(4):53-8. (In Russ.)]. doi: 10.14412/ 2074-2711-2012-422
14. Пирадов МА, Домашенко МА, Максимова МЮ. Реперфузионные методы лечения ишемического инсульта. В кн.: Пирадов МА, Иллариошкин СН, Танашян ММ, редакторы. Неврология XXI века: диагностические, лечебные и исследовательские технологии: Ру- ководство для врачей. Том 2. Москва: АТМО; 2015. С. 9-45. [Piradov MA, Domashenko MA, Maksimova MYu. Reperfusion therapies for ischemic stroke. In: Piradov MA, Illarioshkin SN, Tanashyan MM, editors. Nevrologiya XXI veka: diagnosticheskie, lechebnye i issledovatel'skie tekhnologii: Rukovodstvo dlya vrachei [Neurology of the XXI century: diagnostic, medical and research technology: a Guide for physicians]. Vol. 2. Moscow: ATMO; 2015. P. 9-45.].
15. Скворцова ВИ, Стаховская ЛВ, Лелюк ВГ и др. Становление системы оказания медицинской помощи больным с церебральным инсультом в Российской Федерации. Материалы Всероссийской научно-практической конференции «Совершенствование оказания медицинской помощи больным с сосудистыми заболеваниями». Ярославль; 2011. C. 13–33. Skvortsova VI, Stakhovskaya LV, Lelyuk VG, et al. Formation of system of rendering of medical aid to patients with cerebral stroke in the Russian Federation. Materials of all-Russian scientific-practical conference «Improvement of medical care for patients with vascular disease». Yaroslavl'; 2011. P. 13–33.].
16. Шамалов Н.А. Реперфузионная терапия при ишемическом инсульте в Российской Федерации: проблемы и перспективы. Неврология, нейропсихиатрия, психосоматика. 2014; (спецвыпуск 2): 15-21. [Shamalov NA. Reperfusion therapy for ischemic stroke in Russian Federation: problems and perspectives. Nevrologiya, neiropsikhiatriya, psihosomatika. Neurology, Neuropsychiatry, Psychosomatics. 2011; (Special Issue 2):15-21. (In Russ.)]. doi: http://dx.doi.org/10.14412/2074-2711- 2014-2S-15-21.
17. Rubiera M, Alvarez-SabТn J, Ribo M, et al. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke. 2005 Jul; 36(7):1452-6. doi:10.1161/01.STR.0000170711.43405.81.
18. Breuer L, Blinzler C, Huttner HB, et al. Off-label thrombolysis for acute ischemic stroke: rate, clinical outcome and safety are influenced by the definition of 'minor stroke'. Cerebrovasc Dis. 2011;32(2):177-85. doi: 10.1159/000328811. Epub 2011 Aug 15.
19. Guillan M, Alonso-Canovas A, Garcia-Caldentey J, et al. Off-label intravenous thrombolysis in acute stroke. Eur J Neurol. 2012 Mar;19(3):390-4. doi: 10.1111/j.1468-1331. 2011.03517.x. Epub 2011 Sep 6.
20. Bhatia R, Hill MD, Shobha N, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke. 2010 Oct;41(10):2254-8. doi: 10.1161/STROKEAHA.110.592535. Epub 2010 Sep 9.
21. Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013 Mar 7;368(10):893-903. doi: 10.1056/ NEJMoa1214300. Epub 2013 Feb 7.
22. Riedel CH, Zimmermann P, Jensen-Kondering U, et al. The importance of size: successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length. Stroke. 2011 Jun;42(6): 1775-7. doi: 10.1161/STROKEAHA.110. 609693. Epub 2011 Apr 7.
23. Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2003;(3):CD000213. doi: 10.1002/14651858. CD000213.
24. Lansberg MG, Thijs VN, Bammer R, et al. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke. 2007 Aug;38(8):2275-8. Epub 2007 Jun 14.
25. Whiteley WN, Slot KB, Fernandes P, et al. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke. 2012 Nov;43(11):2904-9. doi: 10.1161/ STROKEAHA.112.665331. Epub 2012 Sep 20.
26. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology. 2002 Sep 24;59(6):862-7.
27. Powers WJ, Derdeyn CP, Jauch EC, et al; American Heart Association Stroke Council. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients with Acute Ischemic Stroke Regarding Endovascular Treatment. A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015 Oct;46(10):3020-35. doi: 10.1161/STR.0000000000000074. Epub 2015 Jun 29.
28. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet. 1997 Jun 7;349(9066):1641-9.
29. IST (International Stroke Trial) Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet. 1997 May 31;349(9065):1569-81.
30. Chen ZM, Sandercock P, Pan HC, et al. Indication for early aspirin use in acute ischemic stroke. A combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke. 2000 Jun;31(6):1240-9.
31. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013 Jul 4;369(1):11-9. doi: 10.1056/NEJMoa1215340. Epub 2013 Jun 26.
32. Zuo FT, Liu H, Wu HJ. The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese Patients A randomized and controlled trail. Medicine (Baltimore). 2017 Jan;96(1):e5497. doi: 10.1097/MD.0000000000005497.
33. Ge F, Lin H, Liu Y, et al. Dual antiplatelet therapy after stroke or transient ischaemic attack – how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and metaanalysis. Eur J Neurol. 2016 Jun;23(6):1051-7. doi: 10.1111/ene.12982. Epub 2016 Mar 28.
34. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack. A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2014 Jul;45(7):2160-236. doi: 10.1161/ STR.0000000000000024. Epub 2014 May 1.
35. Antithrombotic Trialists` Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ. 2002 Jan 12;324(7329):71-86.
36. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994 Jan 8;308(6921):81-106.
37. He J, Whelton P, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998 Dec 9;280(22):1930-5.
38. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996 Nov 16;348(9038):1329-39.
39. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet. 2004 Jul 24-30; 364(9431):331-7.
40. Bhatt DL, Fox KA, Hacke W, et al; CHARISMA investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 Apr 20;354(16):1706-17. Epub 2006 Mar 12.
41. SPS3 Investigators, Benavente OR, Hart RG, McClure LA, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012 Aug 30;367(9):817-25. doi: 10.1056/NEJMoa1204133.
42. The ESPRIT study group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet. 2006 May 20;367 (9523):1665-73.
43. Diener HC, Sacco RL, Yusuf S; Steering Committee of PROFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two Antithrombotic regimen (a fixeddose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with stroke. The Prevention Regimen for Effectively Avoiding Second Strokes Trial (PROFESS). Cerebrovasc Dis. 2007;23(5-6):368-80. Epub 2007 Feb 26.
44. Суслина ЗА, Фонякин АВ, редакторы. Кардионеврология. Справочное руководство с обзором клинических исследований. Москва: ИМА-ПРЕСС; 2011. 264 с. [Suslina ZA, Fonyakin AV, editors. Kardionevrologiya. Spravochnoe rukovodstvo s obzorom klinicheskikh issledovanii [Cardioneurology. Reference manual with the review of clinical research]. Moscow: IMA-PRESS; 2011. 264 p.].
45. Бокерия ЛА, Затевахин ИИ, Кириенко АИ и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология. 2015;9(4): выпуск 2. [Bokeriya LA, Zatevakhin II, Kirienko AI, et al. Russian clinical recommendations for diagnosis, treatment and prevention of venous thromboembolic complications. Flebologiya. 2015;9(4): issue 2. (In Russ.)].
46. Суслина ЗА, Фонякин АВ, Кузнецов АЛ. Кардиоэмболический инсульт: источники эмболии и пути профилактики. Атмосфера. Новости кардиологии. 2004;(2):13-6. [Suslina ZA, Fonyakin AV, Kuznetsov AL. Cardioembolic stroke: source of embolism and ways of prevention. Atmosfera. Novosti kardiologii. 2004;(2):13-6. (In Russ.)].
47. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38): 2893-2962. Epub 2016 Aug 27.
48. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke. 2007 Feb;38(2):423-30. Epub 2007 Jan 4.
49. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013 May;15(5):625-51. doi: 10.1093/ europace/eut083.
Review
For citations:
Maksimova M.Yu., Fonyakin A.V., Geraskina L.A. Antiplatelet therapy strategies for ischemic stroke. Neurology, Neuropsychiatry, Psychosomatics. 2017;9(2):58-64. (In Russ.) https://doi.org/10.14412/2074-2711-2017-2-58-64
Views: 639
Email this article 